GT Biopharma Inc. (NASDAQ:GTBP) on Monday said its recently implemented artificial intelligence-based technologies are improving drug discovery productivity and pipeline development efficiency, with the company expecting additional development candidates to advance into pre-IND development in 2027.
AI Tools Drive Discovery And Engineering Efficiencies
The clinical-stage immuno-oncology company, which develops therapies based on its proprietary natural killer cell engager TriKE platform, said the new AI initiatives have enhanced its drug engineering capabilities and accelerated discovery efforts.
According to Michael Breen, executive chairman and CEO, GT Biopharma is continuing to advance its lead programs, GTB-3650 and GTB-5550, through Phase 1 studies this year while also focusing on next-generation assets that could offer shorter development timelines, improved odds of clinical success, and lower development costs.
AI Supports Candidate Selection And Molecular Design
GT Biopharma said it is using AI-guided sequence and structural analyses to identify new tumor-targeting engagers and multi-domain proteins with favorable characteristics, including binding, stability, and overall developability.
The company said these tools allow researchers to prioritize molecules that are more likely to demonstrate successful translation beyond the discovery stage.
AI technologies are also being used to support molecular engineering efforts by optimizing domain orientation, linker design, and spatial architecture.
GT Biopharma said these refinements are intended to improve binding, promote productive immune synapse formation, and reduce structural issues that could affect potency, manufacturing, or consistency.
Structural Modeling Aims To Streamline Development
In later-stage discovery work, the company said it applies AI-based structural modeling to evaluate factors such as surface exposure, steric compatibility, and assay performance.
GT Biopharma said the modeling helps refine drug constructs before moving into more resource-intensive in vitro and in vivo studies.
GTBP Stock Price Activity: GT Biopharma shares were up 0.38% at $0.48 during premarket trading on Monday, according to Benzinga Pro.
Photo by Gorodenkoff via Shutterstock
Photo by Yuri A via Shuttestock
Recent Comments